3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Glioblastoma
47
Brain Neoplasms
24
Central Nervous System Neoplasms
22
Astrocytoma
16
Glioma
15
Medulloblastoma
11
Neoplasms
8
Oligodendroglioma
7
Lymphoma
7
Recurrence
6
Gliosarcoma
6
Spinal Cord Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, AIDS-Related
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Ependymoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Solid Tumor
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
8
Bevacizumab
8
toripalimab
7
senaparib
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Gemcitabine
5
Fluorouracil
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
spartalizumab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Midazolam
3
Itraconazole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor
×
Lomustine
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled